Tufts CSDD report based on data collected and analyzed financial, personnel, and trend data from 18 top public and private CROs.
Between June and August 2022, Tufts CSDD collected and analyzed financial, personnel, and trend data from 18 top public and private contract research organizations (CROs) to inform the industry on the current status of the CRO industry. This information is contained in the November/December 2022 issue of the Tufts CSDD Impact Report, which can be purchased online.
Topline insights into the data include the following:
The Impact report also summarized the problem of terms and definitions regarding sourcing strategies by sponsor companies that use a wide variety of outsourcing models to support their portfolios. A collaboration between Tufts CSDD, ICON, and a consortium of pharmaceutical companies proposed a new framework to differentiate sourcing models. A chart of which is included in the Impact report, along with a fuller discussion in this article appearing on the Applied Clinical Trials website.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.